الفهرس 
List of FiguresOnly 14 pages are availabe for public view
 |  | from | 197 |  |  |
| | | from | 197 | | |
Abstract
Immunoglobulin-like transcript3 (ILT3), a member of the
immunoglobulin superfamily, is a transmembrane inhibitory receptor
expressed on antigen-presenting cells (APCs) such as monocytes and
dendritic cells (DCs) as well as on endothelial cells .
It is essential for the generation of regulatory T cells in humans,
upregulation of this inhibitory receptor (ILT3) plays a crucial role in graft
adaptation and protection against the recipient’s immune response .
The present study aimed to assess ILT3 expression frequency in
patients with leukemia , and to evaluate its association with the different
clinical and laboratory data, as well as its relation to disease outcome.
Nintey–five adult Egyptian with leukemia were enrolled into this
prospective study divided into 2 groups: 47 acute leukemia and 12
chronic lymphoblastic leukemia (CLL) patients.
Our results was found that the expression of ILT3 is expressed in
19 patients in AML group (59.38%) also ILT3 is expressed only in 3
patients in ALL group (20%) and was expressed in 6 patients (50%) in
CLL group ,ILT3 was expressed by 14/14 cases of AML (M4/M5).
Summary
[142]
ILT3 expression was not associated with any clinical or
laboratory variables, except for WBC Count in the whole acute leukaemia
and CLL patient.
Flow cytometry assessment of ILT3 expression was performed
on blast cells. In Acute Leukemia, there is positive correlations were
elicited between CD85K expression and CD 22, CD117, CD36, SIGM
,HLADR but in CLL group, there was a significant correlation between
CD85K and CD23, CD19, CD45 and CD5.
These findings high lights the potential value of ILT3 as a target
for therapy in AML with monocytic differentiation. Blocking ILT3
signaling with specific antibodies or antagonists may render ILT3 AML
cells more susceptible to differentiation agents and anti-tumor T cell
responses. Also The high frequency of ILT-3 positive in CLL patients
especially with high white cell count suggesting that ILT-3 may have
prognostic value.
Conclusion:
It is concluded that the ILT3 is expressed by leukemia myeloid
precursors as a reliable marker AML with monocytic differentiation
Recommendations:
However, further larger studies are required to support our findings
and to investigate more extensively the role of ILT3 in the development
of leukemia especially monocytic AML and CLL. And also to study their
immunological functions in resistance or susceptibility involved in the
immune response against the proliferation of malignant cells and
prognosis of the disease.